Sign Out
Atopic dermatitis
Adult: Moderate to severe cases which are not adequately controlled with topical treatments, or when topical treatments are not advisable: Initially, 600 mg (given as two consecutive 300 mg inj at different inj sites), followed by 300 mg every other week. Consider treatment discontinuation if there is no response after 16 weeks. May be used with or without topical corticosteroids. Topical calcineurin inhibitors may be used but reserved for problem areas only (e.g. face, neck, intertriginous or genital areas).
Child: Moderate to severe cases: 6-17 years 15-<30 kg: Initially, 600 mg (given as two 300 mg inj at different inj sites), followed by 300 mg every 4 weeks; 30-<60 kg: Initially, 400 mg (given as two 200 mg inj at different inj sites), followed by 200 mg every other week; ≥60 kg: Same as adult dose. Consider treatment discontinuation if there is no response after 16 weeks. Treatment and dosage recommendations may vary among individual products and between countries (refer to specific product guidelines).
Child: Moderate to severe cases: 6-17 years 15-<30 kg: Initially, 600 mg (given as two 300 mg inj at different inj sites), followed by 300 mg every 4 weeks; 30-<60 kg: Initially, 400 mg (given as two 200 mg inj at different inj sites), followed by 200 mg every other week; ≥60 kg: Same as adult dose. Consider treatment discontinuation if there is no response after 16 weeks. Treatment and dosage recommendations may vary among individual products and between countries (refer to specific product guidelines).
Subcutaneous
Asthma
Adult: As add-on maintenance therapy for severe asthma with type 2 inflammation characterised by elevated blood eosinophils and/or raised fraction of exhaled nitric oxide: Initially, 400 mg (given as two consecutive 200 mg inj at different inj sites), followed by 200 mg every other week. For patient with severe asthma on oral corticosteroids, or those with severe asthma with co-morbid moderate to severe atopic dermatitis or with co-morbid severe chronic rhinosinusitis with nasal polyposis: Initially, 600 mg (given as two consecutive 300 mg inj at different inj sites), followed by 300 mg every other week.
Child: ≥12 years Same as adult dose.
Child: ≥12 years Same as adult dose.
Subcutaneous
Chronic rhinosinusitis with nasal polyposis
Adult: As add-on maintenance therapy in patients with inadequately controlled cases: 300 mg once every other week. Treatment recommendations may vary among individual products and between countries (refer to specific product guidelines).
Subcutaneous
Eosinophilic oesophagitis
Adult: 300 mg once weekly. Treatment recommendations may vary among individual products and between countries (refer to specific product guidelines).
Child: ≥12 years ≥40 kg: Same as adult dose.
Child: ≥12 years ≥40 kg: Same as adult dose.
